AlphAIalphai — Financial news for AI agents
fool.comAUG 203 min read$OPRX

OptimizeRx (OPRX) Q2 2026 Earnings Call Transcript

OptimizeRx (OPRX) reported Q2 2026 revenue of $20.5M, down 30% YoY due to lower-margin services and customer inactivity. Adjusted EBITDA was $4.9M. Full-year guidance was reaffirmed: $95M-$100M revenue and $21M-$25M adjusted EBITDA. AI software revenue grew 25% YoY. Cash and cash equivalents were $24.1M, with debt reduced to $19.7M. Management highlighted strategic shifts and leadership transitions. (350 characters)

Original reporting
fool.com
Published Aug 20, 2026, 12:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 20, 2026, 1:07 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
OptimizeRx (OPRX) Q2 2026 Earnings Call Transcript — source image
Source · fool.com
Decision brief

The 30-second read

$OPRXBullishMed
01

Why it matters

Earnings beat and reaffirmed guidance suggest the transition is progressing, but revenue contraction and customer concentration remain risks.

02

Market read

Micro‑cap healthcare‑tech stock with fresh earnings data; relevant for short‑term traders and sector specialists.

03

What to watch

Debt repayment schedule and upcoming CFO transition may affect near‑term liquidity.

Relevance 6/10Novelty 8/10Timing: post‑earnings Q2 2026 release

Background

OptimizeRx is transitioning from low‑margin managed services to higher‑margin AI software for pharma marketers.

Company-level read

Ticker impact

$OPRXBullishHigh confidence
Context

Q2 2026 earnings release with revenue $20.5M, adjusted EBITDA $4.9M, and reaffirmed full-year guidance.

Expected impact

Potential short-term upside as investors digest beat and guidance.

Evidence & confidence

First report of earnings numbers and guidance for a micro‑cap; beat and reaffirmation are actionable.

Market effects

Sector

Highlights AI‑enabled software growth in healthcare advertising sector.

Regional

US healthcare tech niche may see modest re‑rating.

Global

Limited to investors tracking niche pharma‑tech firms.

Counterpoint

What could challenge this read

Revenue decline and high customer concentration could pressure the stock despite earnings beat.

Key entities

  • Executive
    Stephen L. Silvestro

    CEO of OptimizeRx

  • Executive
    Edward Stelmakh

    Chief Financial Strategy Officer, soon to be CFO successor

Read at source← All news

Related articles

AUG 12
$OPRXMed

OptimizeRx Corp (OPRX): Results of Operations and Financial Condition

OptimizeRx Corp (OPRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 5 oprxq22026earningsrelease.htm EX-99.1 Document OptimizeRx Reports Second Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance - Q2 revenue totals $20.5 million - Q2 net loss and adjusted EBITDA of $(0.7) million and $4.9 million, respectively - Reaffirms

SEC EDGAR 8-K4 min
AUG 24
$SPGMedAI 8/10

Why Simon Property Group’s malls are attracting more retailers

Simon Property Group reported strong Q2 results with revenue up 20% to $1.79B. CEO Eli Simon noted high retailer demand, 1,200 leases signed, and 17% positive rent spreads. Portfolio occupancy remained at 96%, with re-leased Saks Off 5th space expected to yield higher rents. FFO was flat at $1.185B, while net income decreased 13.1% to $483.1M. Sales productivity rose 14% to $838 per sq ft.

insideretail.asia3 min
AUG 24
$GILDHighAI 8/10

Gilead’s Core Business Is Accelerating, But Will Its $11 Billion Pipeline Bet Pay Off?

Gilead Sciences (GILD) reported Q2 2026 with double-digit growth in commercial portfolio sales, but posted a significant loss due to $11.2B in R&D expenses from acquisitions. HIV sales rose 12% to $5.7B, while non-HIV areas like liver disease and cancer treatments also showed growth. The company raised its 2026 sales guidance and made strategic acquisitions, but faces risks from clinical development and financial obligations.

insidermonkey.com3 min
AUG 24
$ABBVMedAI 8/10

AbbVie’s Humira Replacement Strategy Is Working, But Could Growth Be Too Concentrated?

AbbVie (NYSE:ABBV) reported Q2 2026 revenue of $16.99B, up 10.2%, driven by immunology and neuroscience. Skyrizi and Rinvoq revenues grew 24.4% and 24.5% respectively, offsetting Humira's 35.9% decline. However, concentration risk exists as these two products made up 47% of revenue. Oncology and aesthetics showed weaker performance, with oncology revenue down 1.5%. Adjusted EPS rose 22.9% to $3.65.

yahoo.com3 min